Diabetes Treatment and Management

Работ: 59

EFFECT OF GLIFLOZINS ON RENAL DYSFUNCTION IN CHRONIC HEART FAILURE WITH ANEMIA
A. G. Gadaev, F. I. Khujakulova
СтатьяDiabetes Treatment and ManagementOriental Journal of Medicine and Pharmacology2023Цитирований: 0
ABI
THE ROLE OF ANGIOTENSIN-CONVERTING ENZYME INHIBITORS AND GLIFLOZINS IN THE TREATMENT OF CHRONIC HEART FAILURE WITH ANEMIA
A. G. Gadaev, F. I. Khujakulova
СтатьяErythropoietin and Anemia TreatmentOriental Journal of Medicine and Pharmacology2023Цитирований: 0
ABI
QАNDLI DIАBET KАSАLLIGINI DAVOLASHDA FOYDALANILADIGAN SINTETIK DORI VOSITALARI VА ULАRNING KIMYOVIY TARKIBI
Go’yoxon Alidjonovna Mo’minova, Ibrohimjon Rahmonovich Asqarov
СтатьяDiabetes Treatment and ManagementJournal of Chemistry of Goods and Traditional Medicine2023Цитирований: 0
ABI
#150 Effect of dapagliflozin in patients with CKD depending on primary kidney disease
Sherzod Abdullaev, Botir Daminov, Olimkhon Sharapov
СтатьяDiabetes Treatment and ManagementNephrology Dialysis Transplantation2024Цитирований: 0
ABI
#206 The effect of dapagliflozin on anemia in patients with CKD
Sherzod Abdullaev, Ranokhon Igamberdieva
СтатьяDiabetes Treatment and ManagementNephrology Dialysis Transplantation2024Цитирований: 0
ABI
Prognostic significance of biomarkers in the early diagnosis of nephropathy in diabetes mellitius II type
Nilufar Akhmedova, Gulnoza Sulaymanova, Kamol Boltayev
СтатьяChronic Kidney Disease and DiabetesBIO Web of Conferences2024Цитирований: 0
ABI
Protective Potential of Sodium-Glucose Cotransporter 2 Inhibitors in Internal Medicine (Part 2)
Ashot Avagimyan, Mohammad Sheibani, А. И. Трофименко +15
СтатьяDiabetes Treatment and ManagementInnovative medicine of Kuban2025Цитирований: 0
ABI
ON THE SIGNIFICANCE OF THE SCORE-2 RISK SCALE FOR CARDIOVASCULAR COMPLICATIONS AMONG PATIENTS WITH PREDIABETES
Shakhnоza Yusupova, Ruhsorakhon Abdurahmanova
СтатьяDiabetes, Cardiovascular Risks, and LipoproteinsMedical science of Uzbekistan2025Цитирований: 0
ABI
Nephroprotective treatment with dapagliflozin in patients with diabetic kidney disease
Olimkhon Sharapov, Sherzod Abdullaev
СтатьяDiabetes Treatment and ManagementNephrology and Dialysis2025Цитирований: 0
ABI
Evaluation of the efficacy of treatment using SGLT2 inhibitors in patients with acute myocardial infarction
Dilafruz Akhmedova, Раиса Тригулова
СтатьяDiabetes Treatment and ManagementAtherosclerosis2025Цитирований: 0
ABI
Prognosis of Hospitalizations of Patients with Different Phenotypes of Heart Failure in Type 2 Diabetes Mellitus
Раиса Тригулова, Alisher Ikramov, Dilafruz Akhmedova +3
СтатьяDiabetes Treatment and ManagementAmerican Heart Journal2025Цитирований: 0
ABI
Cardiovascular Outcomes of SGLT-2 Inhibitors in Hypertensive Patients With and Without Diabetes: A Retrospective Observational Study
Salar Sohail, Talat Bashir, Hajra Tariq +5
СтатьяDiabetes Treatment and ManagementCureus2025Цитирований: 0
ABI
#1796 The impact of metabolic syndrome components on renal function in patients with heart failure
Музаффар Илхомжон Асомов, Gulchehra Atakhodjayeva, Olimkhon Sharapov +1
СтатьяDiabetes Treatment and ManagementNephrology Dialysis Transplantation2025Цитирований: 0
ABI
QANDLI DIABET VA UNING ASORATLARI
Xodjaeva Muqaddas Sati – Maxamatovna,Abdamutova Mahliyo Hasanboy qizi
СтатьяDiabetes, Cardiovascular Risks, and LipoproteinsZenodo (CERN European Organization for Nuclear Research)2025Цитирований: 0
ABI
CLINICAL EFFICACY OF SGLT2 INHIBITORS AND METFORMIN COMBINATION IN PATIENTS WITH TYPE 2 DIABETES MELLITUS
M Rizayeva, M Axmedova
СтатьяDiabetes Treatment and ManagementScientific and Innovative Therapy2025Цитирований: 0
ABI
Central obesity and glycaemic control in newly diagnosed type 2 diabetes mellitus patients: evidence from Uzbekistan
Shukhrat Ziyadullaev, Shokhista Eshmuradova, Jonibek Kadirov +3
ПрепринтDiabetes, Cardiovascular Risks, and LipoproteinsResearch Square2025Цитирований: 0
ABI
Peptide drugs for obesity and type 2 diabetes mellitus: an overview of clinical trials
Haniyeh Barzgar, Darmadi Darmadi, Jabbarova Nafisa +2
Обзорная статьяDiabetes Treatment and ManagementClinica Chimica Acta2025Цитирований: 0
ABI
QANDLI DIABETDA HbA1c KO‘RSATKICHINING KLINIK AHAMIYATI
Yulduzxon Fayzullayeva, Maftuna Yusupova
СтатьяDiabetes, Cardiovascular Risks, and LipoproteinsQO‘QON UNIVERSITETI XABARNOMASI2026Цитирований: 0
ABI
Central obesity and glycaemic control in newly diagnosed type 2 diabetes mellitus patients: evidence from Uzbekistan
Shukhrat Ziyadullaev, Shokhista Eshmuradova, Jonibek Kadirov +3
СтатьяDiabetes, Cardiovascular Risks, and LipoproteinsBMC Endocrine Disorders2026Цитирований: 0
ABI
The Effects of Glucagon-Like Peptide-1 Agonist Therapy (Semaglutide and Tirzepatide) on Metabolic and Hormonal Parameters in Men with Obesity and Insulin Resistance
Mukhammadali Jumayev
СтатьяDiabetes Treatment and ManagementZenodo (CERN European Organization for Nuclear Research)2026Цитирований: 0
ABI
The Effects of Glucagon-Like Peptide-1 Agonist Therapy (Semaglutide and Tirzepatide) on Metabolic and Hormonal Parameters in Men with Obesity and Insulin Resistance
Mukhammadali Jumayev
СтатьяDiabetes Treatment and ManagementZenodo (CERN European Organization for Nuclear Research)2026Цитирований: 0
ABI
The Effects of Glucagon-Like Peptide-1 Agonist Therapy (Semaglutide and Tirzepatide) on Metabolic and Hormonal Parameters in Men with Obesity and Insulin Resistance
Mukhammadali Jumayev
СтатьяDiabetes Treatment and ManagementZenodo (CERN European Organization for Nuclear Research)2026Цитирований: 0
ABI
The Effects of Glucagon-Like Peptide-1 Agonist Therapy (Semaglutide and Tirzepatide) on Metabolic and Hormonal Parameters in Men with Obesity and Insulin Resistance
Mukhammadali Jumayev
СтатьяDiabetes Treatment and ManagementZenodo (CERN European Organization for Nuclear Research)2026Цитирований: 0
ABI
Cost-Effectiveness of Empagliflozin in Patients with Chronic Heart Failureand Chronic Kidney Disease: A Systematic Review
Sultanbaeva Nargiza, Mukhamedova Shohista, Umarova Shakhnoz +1
СтатьяDiabetes Treatment and ManagementCurrent Cardiology Reviews2026Цитирований: 0
ABI
Clinical efficacy of SGLT2 inhibitors in chronic heart failure and chronic kidney disease: a systematic review and meta-analysis
Nargiza Sultanbaeva, Shohista Mukhamedova, Shakhnoz Umarova +1
СтатьяDiabetes Treatment and ManagementCurrent Cardiology Reviews2026Цитирований: 0
ABI